AI Article Synopsis
- The study investigated the use of doxycycline injections as a treatment for persistent olecranon bursitis (OB) that didn’t respond to standard care, comparing it to surgical removal of the bursa.
- Researchers analyzed data from 27 patients treated with doxycycline and 18 who underwent surgery over an 11-year period.
- Results showed that doxycycline had a recurrence rate of 29.6% and high satisfaction levels (85.7%), while surgery had a lower recurrence rate of 16.7%, indicating that doxycycline may be a safe and effective non-surgical alternative for OB treatment.
Article Abstract
Purpose: This study aimed to determine the efficacy and safety of intrabursal injection of doxycycline sclerotherapy to treat olecranon bursitis (OB) refractory to conservative management.
Methods: We retrospectively reviewed 27 patients with recurrent OB who were treated over 11 years with intrabursal injections of doxycycline. They were compared with a control group of 18 patients with recurrent OB who underwent surgical bursectomy. Patients were re-evaluated by the treating physician for recurrence of bursitis and treatment complications and completed a questionnaire to assess satisfaction, pain, and other patient-reported outcomes.
Results: Eight patients (29.6%) undergoing doxycycline sclerotherapy had recurrence, requiring one more doxycycline lavage within the first 4 weeks of initial doxycycline treatment. Three patients (16.7%) undergoing surgery had recurrence after surgery, requiring repeat aspiration. There were no patients in either doxycycline or surgical groups with recurrence of bursitis at the final follow-up (median = 195 and 1,055 days, respectively). No patients in the doxycycline group ultimately required surgical bursectomy, and no patients undergoing surgery required repeat surgeries. A regression model controlling for covariates did not find a significant difference between groups in the likelihood of physician-identified complication or repeat aspiration after doxycycline lavage or surgical bursectomy. Of patients undergoing doxycycline sclerotherapy, 85.7% of patients reported high satisfaction (Likert score: 8-10), and 95.2% reported that they would pursue this treatment again.
Conclusions: Use of intrabursal doxycycline as a sclerosing agent for recurrent OB was safe and effective, with high patient satisfaction and no ultimate recurrence of bursitis at the final follow-up. This may be an effective alternative to surgical bursectomy for patients with recurrent OB refractory to conservative management.
Type Of Study/level Of Evidence: Therapeutic IV.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11331157 | PMC |
| http://dx.doi.org/10.1016/j.jhsg.2024.03.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical and Imaging Outcomes of Doxycycline Exchange Sclerotherapy for Lymphatic Malformations.
J Vasc Interv Radiol
December 2024
The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD. Electronic address:
Purpose: To evaluate serial doxycycline exchanges (SDEs) to treat lymphatic malformations (LMs).
Materials And Methods: Retrospective chart review of patients undergoing LM sclerotherapy with SDEs at our tertiary care academic institution from April 2003 through March 2023. Primary outcome measure was change in symptoms between pre- and post-treatment clinical notes.
Recurrent Aneurysmal Bone Cyst Treated with Percutaneous Doxycycline Sclerotherapy: A Case Report.
JBJS Case Connect
October 2024
Cedars-Sinai Medical Center, Department of Orthopedic Surgery, Los Angeles, California.
Article Synopsis
- * After surgery, the cyst came back aggressively, prompting further intervention.
- * The recurrence was effectively treated using percutaneous doxycycline sclerotherapy, which is considered a low-risk option for such cases.
Outcome evaluation for the treatment of low flow venous and lymphatic malformations.
CVIR Endovasc
November 2024
George's Healthcare NHS Trust, St George's University Hospitals NHS Foundation Trust, London, SW17 0QT, UK.
Purpose: To propose a standardized method of subjectively and objectively evaluating outcomes of sclerotherapy in treating low flow vascular malformations.
Materials And Methods: Sixty-six patients with low flow vascular malformations (venous, lymphatic, or combined) were treated with percutaneous sclerotherapy using bleomycin, doxycycline, or sodium tetradecyl sulphate. Each lesion required between 2-5 sessions of sclerotherapy with 8-week intervals in between.
Outcome of Injection Sclerotherapy With Doxycycline in Lymphatic, and Veno-lymphatic Malformation in Children: A Single Centre Experience.
J Pediatr Surg
November 2024
Department of Paediatric Surgery, CHILDS Trust Medical Research Foundation, Kanchi Kamakoti CHILDS Trust Hospital, Chennai, India.
Aim: Lymphatic malformations (LMs) and Veno-lymphatic malformations (VLMs) are congenital slow flow vascular malformations. Intralesional sclerotherapy is a good alternate option for treatment of LMs and VLMs. Our aim was to evaluate the outcome of doxycycline sclerotherapy for lymphatic and veno-lymphatic malformation in children in our institute.
View Article and Find Full Text PDFDoxycycline Sclerotherapy of Mandibular Aneurysmal Bone Cysts: A Brief Clinical Study.
J Craniofac Surg
September 2024
Department of Radiology, Nationwide Children's Hospital, Columbus, OH.
Article Synopsis
- * This report discusses three pediatric cases where mandibular ABCs were effectively treated with image-guided doxycycline sclerotherapy, highlighting varying presentations and previous treatment experiences among the patients.
- * All patients showed resolution of symptoms and demonstrated successful bone healing without any functional or aesthetic complications, indicating that doxycycline sclerotherapy is a safe and effective treatment option for both new and recurring mandibular ABCs.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!